Has Aglae Rene, MD received payments from drug or device companies?

Yes. Drug and device makers reported $3,532 in general payments to Aglae Rene, MD across 54 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Aglae Rene, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Aglae Rene, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Aglae Rene, MD

Interventional Cardiology · Mount Kisco, NYNPI 1831415090

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $3,085 of the $3,532 with a category attached, or 87.4%. It is spread thinly across 11 manufacturers, the largest accounting for just 23.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $1,585, 3.0 times the $522 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in NY, where the typical reported total is $8,047.

$3,532in general payments, 2019–2025

Across 54 payments — averaging $65.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Spectrawave, Inc$844
Edwards Lifesciences$556
Medtronic$542
Cardiovascular Systems Inc.$370
Shockwave Medical, Inc$363
Boston Scientific$362
plus $495 from 5 others

What the payments were for

Travel & lodging$44713%
Food & beverage$3,08587%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Spectrawave, Inc	6	$844
Edwards Lifesciences	9	$556
Medtronic(2 entities)	12	$542
Cardiovascular Systems Inc.	4	$370
Shockwave Medical, Inc	9	$363
Boston Scientific	3	$362
Abbott	7	$164
E.r. Squibb & Sons, L.L.C.	1	$125
Heartflow, Inc.	1	$111
Irhythm Technologies, Inc.	1	$68
Cathworks, Inc.	1	$28

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

HyperVue Imaging System$764
Starlight Imaging Catheter$764
X1-FFR$637
Edwards SAPIEN 3 Ultra Transcatheter Heart Valve$342
Diamondback Coronary$259
AVVIGO Guidance System$220
Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter$143
CoreValve Evolut$125
CAMZYOS$125
Abre$121
Edwards SAPIEN 3 Transcatheter Heart Valve$115
FFRct$111
CLINICAL TRIAL PRODUCT$110

How this compares

$3,532 in reported general payments places this provider in the 30th percentile of 382 interventional cardiology providers in New York.

See all interventional cardiology providers in New York →

Medicare billing

Part B allowed, 2024

$314,547

Medicare patients

767

Services billed

4,082

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
EliquisApixaban	300	$387,456
XareltoRivaroxaban	120	$147,189
Repatha SureclickEvolocumab	62	$68,741
EntrestoSacubitril/Valsartan	43	$52,221
FarxigaDapagliflozin Propanediol	21	$24,527
JardianceEmpagliflozin	11	$16,623
BrilintaTicagrelor	11	$11,034
Rosuvastatin Calcium	526	$10,128
Metoprolol Succinate	535	$7,638
Atorvastatin Calcium	603	$7,490
Ezetimibe	182	$6,889
Ranolazine ErRanolazine	25	$6,355
Losartan Potassium	289	$3,557
Amlodipine Besylate	486	$3,343
Pravastatin Sodium	176	$2,566

Paid to pharmacies, not to this prescriber.

Other interventional cardiology in Mount Kisco

Sahil ParikhNew York$1.6M
Deepak BhattNew York$1.6M
Martin LeonNew York$1.5M
Evan ShlofmitzRoslyn$951K
Mohamed Azeem LatibBronx$816K
Yili HuangElmhurst$699K
Ali HaiderAstoria$492K
Sripal BangaloreNew York$482K
Ajay KirtaneNew York$462K
David CohenRoslyn$392K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →